J Pathol Transl Med.  2017 May;51(3):242-254. 10.4132/jptm.2017.04.10.

Molecular Testing of Lung Cancers

Affiliations
  • 1Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
  • 2Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 3Department of Pathology, Inha University School of Medicine, Incheon, Korea.
  • 4Department of Pathology, Inje University Ilsan Paik Hospital, Inje University, Goyang, Korea.
  • 5Department of Pathology, Konkuk University School of Medicine, Seoul, Korea.
  • 6Department of Pathology, Dong-A University College of Medicine, Busan, Korea.
  • 7Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 8Department of Pathology, Gachon University Gil Medical Center, Incheon, Korea.
  • 9Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 10Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • 11Department of Pathology, National Cancer Center, Goyang, Korea. gklee@ncc.re.kr

Abstract

Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories"”mutations, gene rearrangements, and amplifications"”and propose expanded guidelines on molecular testing of lung cancers.

Keyword

Lung neoplasms; Molecular testing; Guideline; Precision medicine

MeSH Terms

Biomarkers
Gene Rearrangement
Humans
Lung Neoplasms*
Lung*
Lymphoma
Pathology, Molecular
Phosphotransferases
Precision Medicine
Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Biomarkers
Phosphotransferases
Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Full Text Links
  • JPTM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error